Skip to main content

Table 7 Impact of generic substitution on the storage of pharmaceutical products by the pharmaceutical companies.

From: The impact of generic substitution on the activities of pharmaceutical companies - a survey from the companies' perspective one year and five years after the introduction of generic substitution in finland

 

Survey 2004

Survey 2008

 

Original product companies

(n = 16)

n (%)a

Generic product companies

(n = 7)

n (%)a

Total

(n = 23)

n (%)a

P-value

Original product companies

(n = 15)

n (%)a

Generic product companies

(n = 6)

n (%)a

Total

(n = 21)

n (%)a

P-value

Has generic substitution influenced the storage of pharmaceutical products by your company?

        

No*

4 (25)

3 (43)

7 (30)

0.626

10 (67)

3 (50)

13 (62)

0.631

It has caused over-stocking**

9 (56)

2 (29)

11 (48)

0.371

4 (27)

1 (17)

5 (24)

1.000

It has caused problems with the expiry date of pharmaceutical products***

7 (44)

4 (57)

11 (48)

0.667

3 (20)

3 (50)

6 (29)

0.291

It has caused over-stocking of obligatory stocksb ****

4 (25)

1 (14)

5 (22)

1.000

3 (20)

-

3 (14)

0.526

It has caused problems with the availability of pharmaceutical products*****

4 (25)

1 (14)

5 (22)

1.000

2 (13)

3 (50)

5 (24)

0.115

It has complicated the execution of obligatory storageb ******

2 (12)

1 (14)

3 (13)

0.684

2 (13)

1 (17)

3 (14)

1.000

It has increased returns of pharmaceutical products from pharmacies after the new price corridor is determinedc

-

-

-

-

2 (13)

1 (17)

3 (14)

1.000

  1. * P-value between the 2004 and 2008 surveys in the original product companies (p = 0.032) and in the generic product companies (p = 1.000)
  2. ** P-value between the 2004 and 2008 surveys in the original product companies (p = 0.149) and in the generic product companies (p = 1.000)
  3. *** P-value between the 2004 and 2008 surveys in the original product companies (p = 0.252) and in the generic product companies (p = 1.000)
  4. **** P-value between the 2004 and 2008 surveys in the original product companies (p = 1.000) and in the generic product companies (p = 1.000)
  5. ***** P-value between the 2004 and 2008 surveys in the original product companies (p = 0.654) and in the generic product companies (p = 0.266)
  6. ****** P-value between the 2004 and 2008 surveys in the original product companies (p = 1.000) and in the generic product companies (p = 1.000)
  7. aThe companies could chose several impacts.
  8. bIn Finland, pharmaceutical companies were obligated to store enough pharmaceutical products in certain medicine groups (e.g. antibiotics, cardiovascular medicines, analgesics) to cover ten or five months of consumption of that product until the end of the year 2008. The obligatory stock of pharmaceutical products was based on the average sales of the product during the period from January to September of the previous year. The obligatory storage Act was amended in 2009.
  9. cThe question did not include this alternative in the 2004 survey.